The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta. Novartis’ generics and biosimilars ...
A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim ... on the European market, such as Sandoz’s Zarzio. Philippe Bastide, head of biosimilars at Mundipharma International ...
In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback